Registry of patients with rare cancers in Korea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on collecting data from patients diagnosed with rare cancers in Korea to assess their participation in clinical research. It gathers comprehensive clinical characteristics, survival information, and pathological data, including genomic information. The aim is to better understand the demographics and outcomes of patients with rare cancers, which may inform future research and treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged ≥19 years
* Confirmed rare cancer
* Life expectancy ≥3 months

Exclusion Criteria:

-Serious or unstable medical/psychiatric conditions

Where it's running

• Severance Hospital
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Hyo Song Kim, MD, Ph.D — Yonsei Cencer center
• Study coordinator: Hyo Song Kim, MD, Ph.D
• Email: hyosong77@yuhs.ac
• Phone: 82-2-2228-8124

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Using genome and RNA analysis to guide treatment for advanced rare cancers

  This project will test whether using detailed tumor DNA, RNA and methylation analyses to guide treatment helps adults with advanced rare cancers respond better than standard care.

  Recruiting at 12 sites German Cancer Research Center · Augsburg and 15 other locations · NCT06855134

• Vaccination with Dendritic Cells for Patients with Resected Stage IV Rare Cancers

  This study is testing a new vaccine made from patients' own immune cells to see if it can help people who have had rare stage IV cancers feel better and stay healthy after surgery.

  Recruiting Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, FC · NCT04166006

• Investigating genetic reasons for unusual responses to cancer treatment

  This study is trying to find out how genetic differences in cancer patients affect their responses to treatment, so doctors can tailor therapies to work better for each individual.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT03740503

• Collecting tumor samples to improve cancer treatment matching

  This study is collecting tumor samples from patients with advanced cancer to see if analyzing their genes can help doctors find the best treatments for them.

  Recruiting at 2 sites University Health Network, Toronto · Hamilton, Ontario and 6 other locations · NCT02906943

• AI-assisted Rare-Disease Diagnosis

  A multicenter randomized test to see if an AI diagnostic tool can help doctors make faster, more accurate rare-disease diagnoses for patients with unresolved symptoms.

  Recruiting at 3 sites Peking Union Medical College Hospital · Cangzhou and 11 other locations · NCT07650799

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.